Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer

Video

In Partnership With:

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

Sara A. Hurvitz, MD, associate professor, David Geffen School of Medicine, University of California, Los Angeles (UCLA), medical oncologist, medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director, Santa Monica-UCLA Outpatient Oncology Practices, anddirector, Breast Cancer Clinical Trials Program, UCLA, discusses sequencing therapeutic options for patients with HER2-positive breast cancer. 

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) is a new standard-of-care approach in the second-line setting of HER2-positive breast cancer, Hurvitzsays. Trastuzumab deruxtecan improved patient outcomes compared with ado-trastuzumab emtansine (Kadcyla; T-DM1) and is utilized in patients who have progressed on trastuzumab (Herceptin) and taxane regimens, Hurvitz adds.

Moreover, the phase 2 HER2CLIMB (NCT02614794) trial demonstrated that tucatinib (Tukysa) plus capecitabine and trastuzumab showed activity in patients with brain metastases, Hurvitz emphasizes.

Ongoing efforts to expand HER2-targeted treatment options are ongoing, Hurvitz continues. Several novel HER2-targeted agents are currently in development, as well as additional targeted therapy combinations for this patient population, Hurvitz concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine